Meta-analysis: The effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 8, 2010, Pages 810-823

  Kwok, C S ^a   Loke, Y K ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFECT; DRUG SAFETY; EMBASE; HEART INFARCTION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

AGED; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77949690349     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04247.x     Document Type: Article

References (37)

1. Van Wekum JW, ten Berg JM, Bedenoord AJ. Proton pump inhibitors and clopidogrel: a difficult dilemma. Am Heart J 2009 157 : e43.
2. Moayyedi P, Sadowski DC. Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol 2009 23 : 251 252.
3. Rude MK, Chey WD. Proton-pump inhibitors, clopidogrel and cardiovascular adverse events: fact, fiction or something in between? Gastroenterology 2009 137 : 1168 1171.
4. Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 2009 374 : 952 954.
5. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010 105 : 34 41.
6. Food and Drug Administration. Public Health Advisory 17 November 2009: updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ ucm190825.htm (accessed 15 December 2009).
7. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009 120 : 2310 2312.
8. Loke YK, Price D, Herxheimer A. Adverse effects. In : Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration 2008. Available at: http://www.cochrane- handbook.org.
9. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998 316 : 989 991.
10. Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol 2008 37 : 1142 1147.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 327 : 557 560.
12. Banerjee S, Varghese C, Weideman R, Weideman M, Little BB. P653: proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel. Eur Heart J 2009 30 (Abstract Supplement 92
13. Bhatt DL, Cryer B, Contant CF, et al. COGENT: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Transvascular Cardiovascular Therapeutics Annual Meeting, September 2009, San Francisco, USA (Abstract).
14. Ching G, Li D, McKay M, Mather J, Lundby J. Abstract 4324: pump proton inhibitors increase major adverse cardiovascular events among post-percutaneous coronary intervention patients on clopidogrel. Circulation 2009 120 : S936 7.
15. Dunn SP, Macaulay TE, Brennan DM, et al. Abstract 3999: baseline proton pump inhibitors use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008 118 : S815.
16. Gaspar A, Ribeiro S, Naibas S, et al. P2679: proton pump inhibitors in patients treated with aspirin and clopidogrel. Eur Heart J 2009 30 (Abstract Supplement 444.
17. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2009 [Epub ahead of print].
18. Hall NL, Mathews KD, May HT, et al. Abstract 997: cardiovascular risk associated with concurrent proton pump inhibitor and clopidogrel therapy: how much? How specific? Circulation 2009 120 : S422-a.
19. Ho PM, Maddox TM, Wing L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 301 : 937 944.
20. Jarai R, Brosovic I, Tentzeris I, Farhan S, Unger G, Huber K. P675: effect of proton pump inhibitors on outcome of patients discharged on dual-antiplatelet therapy after percutaneous coronary intervention and stent implantation. Eur Heart J 2009 30 (Abstract Supplement 98.
21. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180 : 713 718.
22. O'Donoghue ML, Braunwalk E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009 374 : 989 997.
23. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008 52 : 1038 1039.
24. Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. JACC 2009 53 (Suppl. 1 A27.
25. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009 120 : 2322 2329.
26. Sarafoff N, Sibbing D, Sonntag U, Schulz S, Schoemig A, Kastrati A. P894: higher stent thrombosis rate after coronary stenting in patients on dula antiplatelet treatment and concomitant treatment with proton pump inhibitors. Eur Heart J 2009 30 (Abstract Supplement 150.
27. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 360 : 363 375.
28. Simon T, Quandealle PH, Machcourt J, et al. P2121: proton pump inhibitors and clopidogrel response on the cardiovascular major events in patients after acute myocardial infarction. Data from the FAST-MI registry of the French society of cardiology. Eur Heart J 2009 30 (Abstract Supplement 335.
29. Stanek EJ, Aubert RE, Glockhard DA, et al. Oral abstract-11: a national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcome Study. Society for Cardiovascular Angiography and Interventions, 2009, Las Vegas, USA.
30. Stockl KM, Le L, Zkharyan A, et al. Abstract 5607: risk of re-hospitalization for patients using clopidogrel with a proton pump inhibitors. Circulation 2009 120 : S1126 7.
31. Sweeny JM, Kini A, Muntner P, Jakkula M, Farkouh M, Sharma S. Abstract 4323: mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents. Circulation 2009 120 : S936.
32. Torgusen R, Chou C, Kaneshige K, et al. Abstract 4542: does proton pump inhibitor use following percutaneous coronary intervention with drug-eluting stents impact clinical outcomes? Circulation 2009 120 : S968.
33. Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Inter Med 2009 48 : 1725 1730.
34. Zairis M, Patsourakos N, Makrygiannis S, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. Eur Heart J 2008 29(Abstract Supplement) : 134.
35. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009 20 : 512 522.
36. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007 176 : 1091 1096.
37. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009 1 : MR000006 doi:.